Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of oral brepocitinib for active non-infectious intermediate, posterior, and panuveitis
MOH_2024-10-01_013679Phase 3Active, not recruiting
- Sponsor
- Priovant Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-infectious intermediate uveitis, Posterior uveitis (non-infectious) and non-infectious panuveitis (NIU) comparing Brepocitinib with Placebo (2 arms). Primary endpoint: Primary endpoint not reported. Started Sep 2024; status: active, not recruiting.
02
Drugs
brepocitinib
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on MOH_2024-10-01_013679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-01_013679.